Aurelie Hanin, Anthony D Jimenez, Margaret Gopaul, Hannah Asbell, Seyhmus Aydemir, Maysaa Merhi Basha, Ayush Batra, Charlotte Damien, Gregory S Day, Onome Eka, Krista Eschbach, Safoora Fatima, Madeline C Fields, Brandon Foreman, Elizabeth E Gerard, Teneille E Gofton, Hiba A Haider, Stephen T Hantus, Sara Hocker, Amy Jongeling, Mariel Kalkach Aparicio, Padmaja Kandula, Peter Kang, Karnig Kazazian, Marissa A Kellogg, Minjee Kim, Jong Woo Lee, Lara V Marcuse, Christopher M McGraw, Wazim Mohamed, Janet Orozco, Cederic M Pimentel, Vineet Punia, Alexandra M Ramirez, Claude Steriade, Aaron F Struck, Olga Taraschenko, Andrew K Treister, Mark S Wainwright, Ji Yeoun Yoo, Sahar Zafar, Daniel J Zhou, Deepti Zutshi, Nicolas Gaspard, Lawrence J Hirsch
In response to the evolving treatment landscape for new-onset refractory status epilepticus (NORSE) and the publication of consensus recommendations in 2022, we conducted a comparative analysis of NORSE management over time. Seventy-seven patients were enrolled by 32 centers, from July 2016 to August 2023, in the NORSE/FIRES biorepository at Yale. Immunotherapy was administered to 88% of patients after a median of 3 days, with 52% receiving second-line immunotherapy after a median of 12 days (anakinra 29%, rituximab 25%, and tocilizumab 19%)...
June 5, 2024: Epilepsia